News & Views

Hannes Snellman Counsel to Oasmia Pharmaceutical AB on its SEK 399 Million Rights Issue

11 November 2019

Hannes Snellman acted as counsel to Oasmia Pharmaceutical AB, listed on Nasdaq Stockholm, Mid Cap, on its SEK 399 million issue of new shares with preferential rights for existing shareholders. Oasmia Pharmaceutical AB’s largest shareholder, Per Arwidsson (through Arwidsro Investment AB and related parties), committed to subscribe for new shares corresponding to his pro rata holdings in Oasmia Pharmaceutical AB.

Hannes Snellman’s core team included Christoffer Saidac, Mattias Friberg, Khaled Talayhan, Jonas Sjöberg, Marcus Lehtinen, Emma Greiff and Ebba Almén.